{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T23:31:27Z","timestamp":1778628687983,"version":"3.51.4"},"reference-count":151,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd013600","type":"journal-article","created":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T13:54:38Z","timestamp":1589464478000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review"],"prefix":"10.1002","author":[{"given":"Sarah J","family":"Valk","sequence":"additional","affiliation":[{"name":"Jon J van Rood Center for Clinical Transfusion Research; Sanquin\/Leiden University Medical Center; Leiden Netherlands"},{"name":"Department of Clinical Epidemiology; Leiden University Medical Center; Leiden Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Piechotta","sequence":"additional","affiliation":[{"name":"Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khai Li","family":"Chai","sequence":"additional","affiliation":[{"name":"Transfusion Research Unit, School of Public Health and Preventive Medicine; Monash University; Melbourne Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn","family":"Doree","sequence":"additional","affiliation":[{"name":"Systematic Review Initiative; NHS Blood and Transplant; Oxford UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ina","family":"Monsef","sequence":"additional","affiliation":[{"name":"Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica M","family":"Wood","sequence":"additional","affiliation":[{"name":"Transfusion Research Unit, School of Public Health and Preventive Medicine; Monash University; Melbourne Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abigail","family":"Lamikanra","sequence":"additional","affiliation":[{"name":"Clinical, Research and Development; NHS Blood and Transplant; Oxford UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Kimber","sequence":"additional","affiliation":[{"name":"Systematic Review Initiative; NHS Blood and Transplant; Oxford UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoe","family":"McQuilten","sequence":"additional","affiliation":[{"name":"Transfusion Research Unit, School of Public Health and Preventive Medicine; Monash University; Melbourne Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia","family":"So-Osman","sequence":"additional","affiliation":[{"name":"Sanquin Blood Bank; Amsterdam Netherlands"},{"name":"Erasmus Medical Centre; Rotterdam Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lise J","family":"Estcourt","sequence":"additional","affiliation":[{"name":"Haematology\/Transfusion Medicine; NHS Blood and Transplant; Oxford UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Skoetz","sequence":"additional","affiliation":[{"name":"Cochrane Cancer, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,5,14]]},"reference":[{"issue":"14","key":"10.1002\/14651858.CD013600-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.3346\/jkms.2020.35.e149","article-title":"Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Korea","volume":"35","author":"Ahn","year":"2020","journal-title":"Journal of Korean Medical Science"},{"key":"10.1002\/14651858.CD013600-BIB0002|cit2","doi-asserted-by":"crossref","unstructured":"Duan K Liu B Li C Zhang H Yu T Qu J Effectiveness of convalescent plasma therapy in severe COVID-19 patients National Academy of Sciences of the United States of America 2020 10.1073\/pnas.2004168117","DOI":"10.1073\/pnas.2004168117"},{"key":"10.1002\/14651858.CD013600-BIB0003|cit3","doi-asserted-by":"crossref","unstructured":"Duan K Liu B Li C Zhang H Yu T Qu J The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study medRxiv 2020 101\/2020.03.16.20036145","DOI":"10.1101\/2020.03.16.20036145"},{"key":"10.1002\/14651858.CD013600-BIB0004|cit4","doi-asserted-by":"crossref","unstructured":"Pei S Yuan X Zhimin ZZ Run YR Xie Y Minxue SM Convalescent plasma to treat COVID-19: Chinese strategy and experiences medRxiv 2020 10.1101\/2020.04.07.20056440","DOI":"10.1101\/2020.04.07.20056440"},{"key":"10.1002\/14651858.CD013600-BIB0005|cit5","doi-asserted-by":"crossref","unstructured":"Shen C Wang Z Zhao F Yang Y Li J Yuan J Treatment of 5 critically ill patients with COVID-19 with convalescent plasma JAMA 2020 10.1001\/jama.2020.4783","DOI":"10.1001\/jama.2020.4783"},{"key":"10.1002\/14651858.CD013600-BIB0006|cit6","doi-asserted-by":"crossref","unstructured":"Tan L Kang X Zhang B Zheng S Liu B Yu T A special case of COVID-19 with long duration of viral shedding for 49 days medRxiv 2020 10.1101\/2020.03.22.20040071","DOI":"10.1101\/2020.03.22.20040071"},{"key":"10.1002\/14651858.CD013600-BIB0007|cit7","doi-asserted-by":"crossref","unstructured":"Ye M Fu D Ren Y Wang F Wang D Zhang F Treatment with convalescent plasma for COVID-19 patients in Wuhan, China Journal of Medical Virology 2020 10.1002\/jmv.25882","DOI":"10.1002\/jmv.25882"},{"key":"10.1002\/14651858.CD013600-BIB0008|cit8","unstructured":"Zhang B Liu S Tan T Huang W Dong Y Chen L Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection Chest 10.1016\/j.chest.2020.03.039"},{"key":"10.1002\/14651858.CD013600-BIB0009|cit9","doi-asserted-by":"crossref","unstructured":"Zhang L Pang R Xue X Bao J Ye S Dai Y Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19 Aging 12 10.18632\/aging.103102","DOI":"10.18632\/aging.103102"},{"key":"10.1002\/14651858.CD013600-BIB0010|cit10","doi-asserted-by":"crossref","unstructured":"Bloch EM Shoham S Casadevall A Sachais BS Shaz B Winters JL Deployment of convalescent plasma for the prevention and treatment of COVID-19 Journal of Clinical Investigation 2020 10.1172\/JCI138745","DOI":"10.1172\/JCI138745"},{"issue":"3","key":"10.1002\/14651858.CD013600-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"ofaa102","DOI":"10.1093\/ofid\/ofaa102","article-title":"High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019","volume":"7","author":"Cao","year":"2020","journal-title":"Open Forum Infectious Diseases"},{"issue":"4","key":"10.1002\/14651858.CD013600-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1172\/JCI138003","article-title":"The convalescent sera option for containing COVID-19","volume":"130","author":"Casadevall","year":"2020","journal-title":"Journal of Clinical Investigation"},{"key":"10.1002\/14651858.CD013600-BIB0013|cit13","first-page":"27","article-title":"Convalescent plasma as a potential therapy for COVID-19","volume":"27","author":"Chen","year":"2020","journal-title":"Lancet Infectious Diseases"},{"key":"10.1002\/14651858.CD013600-BIB0014|cit14","unstructured":"ChiCTR2000030312 Cancelled, due to modify the protocol A single-center, open-label and single arm trial to evaluate the efficacy and safety of anti-SARS-CoV-2 inactivated convalescent plasma in the treatment& www.chictr.org.cn\/showproj.aspx?proj=50258"},{"key":"10.1002\/14651858.CD013600-BIB0015|cit15","unstructured":"ChiCTR2000030381 Cancelled by investigator A randomized, open-label, controlled and single-center trial to evaluate the efficacy and safety of anti-SARS-CoV-2 inactivated convalescent plasma in the treatment of novel coronavirus pneumonia (COVID-19) patient www.chictr.org.cn\/showproj.aspx?proj=50290"},{"key":"10.1002\/14651858.CD013600-BIB0016|cit16","unstructured":"ChiCTR2000030442 Combination of tocilizumab, IVIG and CRRT in severe patients with novel coronavirus pneumonia (COVID-19) www.chictr.org.cn\/showproj.aspx?proj=50380"},{"key":"10.1002\/14651858.CD013600-BIB0017|cit17","doi-asserted-by":"crossref","unstructured":"D\u00edez JM Romero C Gajardo R Currently available intravenous immunoglobulin (Gamunex-C and Flebogamma\u00a9 DIF) contains antibodies reacting against SARS-CoV-2 antigens bioRxiv 2020 10.1101\/2020.04.07.029017","DOI":"10.1101\/2020.04.07.029017"},{"key":"10.1002\/14651858.CD013600-BIB0018|cit18","first-page":"16","article-title":"Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin","volume":"16","author":"Hu","year":"2020","journal-title":"European Heart Journal"},{"issue":"7","key":"10.1002\/14651858.CD013600-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.3390\/ijms21072272","article-title":"Could intravenous immunoglobulin collected from recovered coronavirus patients protect against COVID-19 and strengthen the immune system of new patients?","volume":"21","author":"Jawhara","year":"2020","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1002\/14651858.CD013600-BIB0020|cit20","unstructured":"NCT04261426 The efficacy of intravenous immunoglobulin therapy for severe 2019-nCoV infected pneumonia clinicaltrials.gov\/ct2\/show\/NCT04261426"},{"key":"10.1002\/14651858.CD013600-BIB0021|cit21","unstructured":"NCT04323800 Convalescent plasma to stem coronavirus: a randomized, blinded phase 2 study comparing the efficacy and safety human coronavirus immune plasma (HCIP) vs. control (SARS-CoV-2 non-immune plasma) among adults exposed to COVID-19 clinicaltrials.gov\/show\/NCT04323800"},{"key":"10.1002\/14651858.CD013600-BIB0022|cit22","unstructured":"NCT04325672 Convalescent plasma to limit coronavirus associated complications: an open label, phase 2A study of high-titer anti-SARS-CoV-2 plasma in hospitalized patients with COVID-19 clinicaltrials.gov\/show\/NCT04325672"},{"key":"10.1002\/14651858.CD013600-BIB0023|cit23","unstructured":"NCT04344015 COVID-19 plasma collection ClinicalTrials.gov\/show\/NCT04344015"},{"key":"10.1002\/14651858.CD013600-BIB0024|cit24","unstructured":"NCT04344977 COVID-19 plasma collection clinicaltrials.gov\/ct2\/show\/NCT04344977"},{"key":"10.1002\/14651858.CD013600-BIB0025|cit25","doi-asserted-by":"crossref","unstructured":"Roback JD Guarner J Convalescent plasma to treat COVID-19: possibilities and challenges JAMA 2020 10.1001\/jama.2020.4940","DOI":"10.1001\/jama.2020.4940"},{"key":"10.1002\/14651858.CD013600-BIB0026|cit26","doi-asserted-by":"crossref","unstructured":"Shi H Zhou C He P Huang S Duan Y Wang X Successful treatment of plasma exchange followed by intravenous immunoglobulin in a critically ill patient with 2019 novel coronavirus infection International Journal of Antimicrobial Agents 2020 105974","DOI":"10.1016\/j.ijantimicag.2020.105974"},{"key":"10.1002\/14651858.CD013600-BIB0027|cit27","first-page":"13","article-title":"COVID-19: herd immunity and convalescent plasma transfer therapy","volume":"13","author":"Syal","year":"2020","journal-title":"Journal of Medical Virology"},{"key":"10.1002\/14651858.CD013600-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"m1256","DOI":"10.1136\/bmj.m1256","article-title":"Covid-19: FDA approves use of convalescent plasma to treat critically ill patients","volume":"368","author":"Tanne","year":"2020","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD013600-BIB0029|cit29","doi-asserted-by":"crossref","unstructured":"Tiberghien P de Lambalerie X Morel P Gallian P Lacombe K Yazdanpanah Y Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how Vox Sanguinis 2020 10.1111\/vox.12926","DOI":"10.1111\/vox.12926"},{"key":"10.1002\/14651858.CD013600-BIB0030|cit30","doi-asserted-by":"crossref","unstructured":"Wong HK Lee CK Pivotal role of convalescent plasma in managing emerging infectious diseases Vox Sanguinis 2020 10.1111\/vox.12927","DOI":"10.1111\/vox.12927"},{"key":"10.1002\/14651858.CD013600-BIB0031|cit31","doi-asserted-by":"crossref","unstructured":"Xie Y Cao S Li Q Chen E Dong H Zhang W Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19 Journal of Infection 2020 S0163 4453(20)30172-9","DOI":"10.1016\/j.jinf.2020.03.044"},{"issue":"14","key":"10.1002\/14651858.CD013600-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.3346\/jkms.2020.35.e150","article-title":"Convalescent plasma therapy for corona virus disease 2019: a long way to go but worth trying","volume":"35","author":"Yoo","year":"2020","journal-title":"Journal of Korean Medical Science"},{"key":"10.1002\/14651858.CD013600-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"104358","DOI":"10.1016\/j.jcv.2020.104358","article-title":"Challenges of convalescent plasma therapy on COVID-19","volume":"127","author":"Zhao","year":"2020","journal-title":"Journal of Clinical Virology"},{"issue":"0","key":"10.1002\/14651858.CD013600-BIB0034|cit34","first-page":"E004","article-title":"The report of two cases infection with novel coronavirus (2019-ncov) after kidney transplantation and the association literature analyzation","volume":"41","author":"Qiu","year":"2020","journal-title":"Chinese Journal of Organ Transplantation"},{"issue":"0","key":"10.1002\/14651858.CD013600-BIB0035|cit35","first-page":"E005","article-title":"Two clinical cases of novel coronavirus pneumonia (NCP) in renal transplant recipients","volume":"41","author":"Tu","year":"2020","journal-title":"Chinese Journal of Organ Transplantation"},{"key":"10.1002\/14651858.CD013600-BIB0036|cit36","unstructured":"ChiCTR2000029757 Convalescent plasma for the treatment of severe and critical novel coronavirus pneumonia (COVID-19): a prospective randomized controlled trial www.chictr.org.cn\/showproj.aspx?proj=49081"},{"key":"10.1002\/14651858.CD013600-BIB0037|cit37","unstructured":"ChiCTR2000029850 Effecacy and safety of convalescent plasma treatment for severe patients with novel coronavirus pneumonia (COVID-19): a prospective cohort study www.chictr.org.cn\/showproj.aspx?proj=49533"},{"key":"10.1002\/14651858.CD013600-BIB0038|cit38","unstructured":"ChiCTR2000030010 A randomized, double-blind, parallel-controlled, trial to evaluate the efficacy and safety of anti-SARS-CoV-2 virus inactivated plasma in the treatment of severe novel coronavirus pneumonia patients (COVID-19) www.chictr.org.cn\/showproj.aspx?proj=49777"},{"key":"10.1002\/14651858.CD013600-BIB0039|cit39","unstructured":"ChiCTR2000030039 Clinical study for infusing convalescent plasma to treat patients with new coronavirus pneumonia (COVID-19) www.chictr.org.cn\/showproj.aspx?proj=49544"},{"key":"10.1002\/14651858.CD013600-BIB0040|cit40","unstructured":"ChiCTR2000030179 Experimental study of novel coronavirus pneumonia rehabilitation plasma therapy severe novel coronavirus pneumonia (COVID-19) www.chictr.org.cn\/showproj.aspx?proj=50059"},{"key":"10.1002\/14651858.CD013600-BIB0041|cit41","unstructured":"ChiCTR2000030627 Study on the application of convalescent plasma therapy in severe COVID-19 www.chictr.org.cn\/showproj.aspx?proj=50727"},{"key":"10.1002\/14651858.CD013600-BIB0042|cit42","unstructured":"ChiCTR2000030702 Convalescent plasma for the treatment of common COVID-19: a prospective randomized controlled trial www.chictr.org.cn\/showproj.aspx?proj=50537"},{"key":"10.1002\/14651858.CD013600-BIB0043|cit43","unstructured":"ChiCTR2000030841 Treatment of acute severe COVID-19 with immunoglobulin from cured COVID-19 patients www.chictr.org.cn\/showproj.aspx?proj=51072"},{"key":"10.1002\/14651858.CD013600-BIB0044|cit44","unstructured":"ChiCTR2000030929 A randomized, double-blind, parallel-controlled trial to evaluate the efficacy and safety of anti-SARS-CoV-2 virus inactivated plasma in the treatment of severe novel coronavirus pneumonia (COVID-19) www.chictr.org.cn\/showproj.aspx?proj=50696"},{"key":"10.1002\/14651858.CD013600-BIB0045|cit45","unstructured":"ChiCTR2000031501 The efficacy of convalescent plasma in patients with critical novel coronavirus pneumonia (COVID-19): a pragmatic, prospective cohort study www.chictr.org.cn\/showproj.aspx?proj=50254"},{"key":"10.1002\/14651858.CD013600-BIB0046|cit46","unstructured":"EUCTR2020-001310-38 A randomized, prospective, open label clinical trial on the use of convalescent plasma compared to best supportive care in patients with severe COVID-19 www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2020-001310-38"},{"key":"10.1002\/14651858.CD013600-BIB0047|cit47","unstructured":"IRCT20151228025732N53 Therapeutic effects of plasma of recovered people from COVID-19 on hospitalized patients with this disease en.irct.ir\/trial\/46931"},{"key":"10.1002\/14651858.CD013600-BIB0048|cit48","unstructured":"IRCT20200310046736N1 Comparison of the therapeutic effect of convalescent plasma and plasma-derived immunoglobulin-enriched solution on COVID-19 patients en.irct.ir\/trial\/46424"},{"key":"10.1002\/14651858.CD013600-BIB0049|cit49","unstructured":"IRCT20200325046860N1 Convalescent plasma therapy for COVID-19 patients en.irct.ir\/trial\/46759"},{"key":"10.1002\/14651858.CD013600-BIB0050|cit50","unstructured":"IRCT20200404046948N1 Efficacy and safety of convalescent plasma in the treatment of COVID-19 en.irct.ir\/trial\/46973"},{"key":"10.1002\/14651858.CD013600-BIB0051|cit51","unstructured":"IRCT20200409047007N1 Effect of COVID 19 survivors plasma in COVID 19 patients with ARDS en.irct.ir\/trial\/47058"},{"key":"10.1002\/14651858.CD013600-BIB0052|cit52","unstructured":"IRCT20200413047056N1 Comparison between the efficacy of intravenous immunoglobulin and convalescent plasma in COVID-19 en.irct.ir\/trial\/47212"},{"key":"10.1002\/14651858.CD013600-BIB0053|cit53","unstructured":"NCT04264858 An exploratory clinical study on the treatment of acute severe 2019-nCoV pneumonia with immunoglobulin from cured 2019-nCoV pneumonia patients clinicaltrials.gov\/show\/NCT04264858"},{"key":"10.1002\/14651858.CD013600-BIB0054|cit54","unstructured":"NCT04292340 The efficacy and safety of anti-SARS-CoV-2 inactivated convalescent plasma in the treatment of novel coronavirus pneumonia patient (COVID-19): an observational study clinicaltrials.gov\/show\/NCT04292340"},{"key":"10.1002\/14651858.CD013600-BIB0055|cit55","unstructured":"NCT04321421 Plasma from donors recovered from new coronavirus 2019 as therapy for critical patients with COVID-19 clinicaltrials.gov\/show\/NCT04321421"},{"key":"10.1002\/14651858.CD013600-BIB0056|cit56","unstructured":"NCT04327349 Investigating effect of convalescent plasma on COVID-19 patients outcome: a clinical trial clinicaltrials.gov\/show\/NCT04327349"},{"key":"10.1002\/14651858.CD013600-BIB0057|cit57","unstructured":"NCT04332380 Convalescent plasma for patients with COVID-19: a pilot study clinicaltrials.gov\/show\/NCT04332380"},{"key":"10.1002\/14651858.CD013600-BIB0058|cit58","unstructured":"NCT04332835 Convalescent plasma for patients with COVID-19: a randomized, open label, parallel, controlled clinical study clinicaltrials.gov\/show\/NCT04332835"},{"key":"10.1002\/14651858.CD013600-BIB0059|cit59","unstructured":"NCT04333251 Evaluating convalescent plasma to decrease coronavirus associated complications. A phase I study comparing the efficacy and safety of high-titer anti-Sars-CoV-2 plasma vs best supportive care in hospitalized patients with interstitial pneumonia due to COVID-19 clinicaltrials.gov\/show\/NCT04333251"},{"key":"10.1002\/14651858.CD013600-BIB0060|cit60","unstructured":"NCT04333355 Phase 1 study to evaluate the safety of convalescent plasma as an adjuvant therapy in patients with SARS-CoV-2 infection clinicaltrials.gov\/show\/NCT04333355"},{"key":"10.1002\/14651858.CD013600-BIB0061|cit61","unstructured":"NCT04338360 Expanded access to convalescent plasma for the treatment of patients with COVID-19 ClinicalTrials.gov\/show\/NCT04338360"},{"key":"10.1002\/14651858.CD013600-BIB0062|cit62","unstructured":"NCT04340050 COVID-19 convalescent plasma ClinicalTrials.gov\/show\/NCT04340050"},{"key":"10.1002\/14651858.CD013600-BIB0063|cit63","unstructured":"NCT04342182 Convalescent plasma as therapy for Covid-19 severe SARS-CoV-2 disease (CONCOVID Study) (ConCoVid-19) ClinicalTrials.gov\/show\/NCT04342182"},{"key":"10.1002\/14651858.CD013600-BIB0064|cit64","unstructured":"NCT04343261 Convalescent plasma in the treatment of COVID 19 ClinicalTrials.gov\/show\/NCT04343261"},{"key":"10.1002\/14651858.CD013600-BIB0065|cit65","unstructured":"NCT04343755 Convalescent plasma as treatment for hospitalized subjects with COVID-19 infection ClinicalTrials.gov\/show\/NCT04343755"},{"key":"10.1002\/14651858.CD013600-BIB0066|cit66","unstructured":"NCT04344535 Convalescent plasma vs. standard plasma for COVID-19 ClinicalTrials.gov\/show\/NCT04344535"},{"key":"10.1002\/14651858.CD013600-BIB0067|cit67","unstructured":"EUCTR2020-001367-88-DK Efficacy and safety of novel treatment options for adults with COVID-19 pneumonia apps.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2020-001367-88-DK"},{"key":"10.1002\/14651858.CD013600-BIB0068|cit68","unstructured":"NCT04345289 Efficacy and safety of novel treatment options for adults with COVID-19 pneumonia (CCAP) ClinicalTrials.gov\/show\/NCT04345289"},{"key":"10.1002\/14651858.CD013600-BIB0069|cit69","unstructured":"NCT04345523 Convalescent plasma therapy vs. SOC for the treatment of COVID19 in hospitalized patients (ConPlas-19) ClinicalTrials.gov\/show\/NCT04345523"},{"key":"10.1002\/14651858.CD013600-BIB0070|cit70","unstructured":"NCT04345679 Anti COVID-19 convalescent plasma therapy ClinicalTrials.gov\/show\/NCT04345679"},{"key":"10.1002\/14651858.CD013600-BIB0071|cit71","unstructured":"NCT04345991 Efficacy of convalescent plasma to treat COVID-19 patients, a nested trial in the CORIMUNO-19 cohort ClinicalTrials.gov\/show\/NCT04345991"},{"key":"10.1002\/14651858.CD013600-BIB0072|cit72","unstructured":"NCT04346446 Efficacy of convalescent plasma therapy in severely sick COVID-19 patients ClinicalTrials.gov\/show\/NCT04346446"},{"key":"10.1002\/14651858.CD013600-BIB0073|cit73","unstructured":"NCT04346589 Convalescent antibodies infusion in critically ill COVID 19 patients clinicaltrials.gov\/ct2\/show\/NCT04346589"},{"key":"10.1002\/14651858.CD013600-BIB0074|cit74","unstructured":"NCT04347681 Potential efficacy of convalescent plasma to treat severe COVID-19 and patients at high risk of developing severe COVID-19 ClinicalTrials.gov\/show\/NCT04347681"},{"key":"10.1002\/14651858.CD013600-BIB0075|cit75","unstructured":"NCT04348656 Convalescent plasma for hospitalized adults with COVID-19 respiratory illness (CONCOR-1) ClinicalTrials.gov\/show\/NCT04348656"},{"key":"10.1002\/14651858.CD013600-BIB0076|cit76","unstructured":"NCT04348877 Plasma rich antibodies from recovered patients from COVID19 ClinicalTrials.gov\/show\/NCT04348877"},{"key":"10.1002\/14651858.CD013600-BIB0077|cit77","unstructured":"NCT04352751 Experimental use of convalescent plasma for passive immunization in current COVID-19 pandemic in Pakistan in 2020 ClinicalTrials.gov\/show\/NCT04352751"},{"key":"10.1002\/14651858.CD013600-BIB0078|cit78","unstructured":"NCT04353206 Convalescent plasma in ICU patients with COVID-19-induced respiratory failure ClinicalTrials.gov\/show\/NCT04353206"},{"key":"10.1002\/14651858.CD013600-BIB0079|cit79","unstructured":"NCT04354831 A study evaluating the efficacy and safety of high-titer anti-SARS-CoV-2 plasma in hospitalized patients with COVID-19 infection clinicaltrials.gov\/ct2\/show\/NCT04354831"},{"key":"10.1002\/14651858.CD013600-BIB0080|cit80","unstructured":"NCT04355767 Convalescent plasma vs. placebo in emergency room patients with COVID-19 clinicaltrials.gov\/ct2\/show\/NCT04355767"},{"key":"10.1002\/14651858.CD013600-BIB0081|cit81","unstructured":"NCT04355897 CoVID-19 plasma in treatment of COVID-19 patients clinicaltrials.gov\/ct2\/show\/NCT04355897"},{"key":"10.1002\/14651858.CD013600-BIB0082|cit82","unstructured":"NCT04356482 Convalescent plasma for ill patients by COVID-19 ClinicalTrials.gov\/show\/NCT04356482"},{"key":"10.1002\/14651858.CD013600-BIB0083|cit83","unstructured":"NCT04356534 Convalescent plasma trial in COVID -19 patients ClinicalTrials.gov\/show\/NCT04356534"},{"key":"10.1002\/14651858.CD013600-BIB0084|cit84","unstructured":"NCT04357106 COPLA study: treatment of severe forms of coronavirus infection with convalescent plasma ClinicalTrials.gov\/show\/NCT04357106"},{"key":"10.1002\/14651858.CD013600-BIB0085|cit85","unstructured":"Bao L Deng W Gao H Xiao C Liu J Xue J Reinfection could not occur in SARS-CoV-2 infected rhesus macaques bioRxiv 10.1101\/2020.03.13.990226"},{"issue":"2","key":"10.1002\/14651858.CD013600-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s10067-019-04832-7","article-title":"Transfusion-related acute lung injury (TRALI) after intravenous immunoglobulins: French multicentre study and literature review","volume":"39","author":"Baudel","year":"2020","journal-title":"Clinical Rheumatology"},{"issue":"6","key":"10.1002\/14651858.CD013600-BIB0087|cit87","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/S2213-2600(17)30174-1","article-title":"Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study","volume":"5","author":"Beigel","year":"2017","journal-title":"Lancet Respiratory Medicine"},{"issue":"11","key":"10.1002\/14651858.CD013600-BIB0088|cit88","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/S2213-2600(19)30199-7","article-title":"Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial","volume":"7","author":"Beigel","year":"2019","journal-title":"Lancet Respiratory Medicine"},{"issue":"2","key":"10.1002\/14651858.CD013600-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1046\/j.1365-2249.2003.02199.x","article-title":"Prospective audit of adverse reactions occurring in 459 primary antibody-deficient patients receiving intravenous immunoglobulin","volume":"133","author":"Brennan","year":"2003","journal-title":"Clinical and Experimental Immunology"},{"key":"10.1002\/14651858.CD013600-BIB0090|cit90","unstructured":"Centers for Disease Control and Prevention (CDC) Coronavirus Disease 2019 (COVID-19) www.cdc.gov\/coronavirus\/2019-ncov\/covid-data\/covidview\/index.html"},{"key":"10.1002\/14651858.CD013600-BIB0091|cit91","unstructured":"Centers for Disease Control and Prevention (CDC) Interim clinical guidance for management of patients with confirmed coronavirus disease (COVID-19) www.cdc.gov\/coronavirus\/2019-ncov\/hcp\/clinical-guidance-management-patients.html"},{"issue":"4","key":"10.1002\/14651858.CD013600-BIB0092|cit92","doi-asserted-by":"publisher","first-page":"393","DOI":"10.3343\/alm.2016.36.4.393","article-title":"Possible transfusion-related acute lung injury following convalescent plasma transfusion in a patient with Middle East respiratory syndrome","volume":"36","author":"Chun","year":"2016","journal-title":"Annals of Laboratory Medicine"},{"key":"10.1002\/14651858.CD013600-BIB0093|cit93","unstructured":"Core outcome set developers\u2019 response to COVID-19 (2nd April 2020) www.comet-initiative.org\/Studies\/Details\/1538"},{"key":"10.1002\/14651858.CD013600-BIB0094|cit94","unstructured":"Veritas Health Innovation Covidence"},{"issue":"11","key":"10.1002\/14651858.CD013600-BIB0095|cit95","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S2213-2600(19)30253-X","article-title":"Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial","volume":"7","author":"","year":"2019","journal-title":"Lancet Respiratory Medicine"},{"key":"10.1002\/14651858.CD013600-BIB0096|cit96","doi-asserted-by":"crossref","unstructured":"Deeks JJ Higgins JP Altman DG editor(s) Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019 Available from www.training.cochrane.org\/handbook","DOI":"10.1002\/9781119536604.ch10"},{"issue":"18","key":"10.1002\/14651858.CD013600-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1016\/j.jacc.2020.03.031","article-title":"Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic","volume":"75","author":"Driggin","year":"2020","journal-title":"Journal of the American College of Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD013600-BIB0098|cit98","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.iac.2008.06.004","article-title":"History of immunoglobulin replacement","volume":"28","author":"Eibl","year":"2008","journal-title":"Immunology and Allergy Clinics of North America"},{"key":"10.1002\/14651858.CD013600-BIB0099|cit99","unstructured":"Cochrane Effective Practice and Organisation of Care (EPOC) What study designs can be considered for inclusion in an EPOC review and what should they be called? EPOC Resources for review authors Available from epoc.cochrane.org\/resources\/epoc-resources-review-authors"},{"key":"10.1002\/14651858.CD013600-BIB0100|cit100","unstructured":"McMaster University (developed by Evidence Prime) GRADEpro GDT"},{"key":"10.1002\/14651858.CD013600-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD013600-BIB0102|cit102","doi-asserted-by":"crossref","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ editor(s) Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019 Available from www.training.cochrane.org\/handbook","DOI":"10.1002\/9781119536604"},{"key":"10.1002\/14651858.CD013600-BIB0103|cit103","doi-asserted-by":"crossref","unstructured":"Higgins JP Deeks JJ editor(s) Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019 Available from www.training.cochrane.org\/handbook","DOI":"10.1002\/9781119536604"},{"issue":"11","key":"10.1002\/14651858.CD013600-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.3201\/eid1111.040659","article-title":"Neutralizing antibody response and SARS severity","volume":"11","author":"Ho","year":"2005","journal-title":"Emerging Infectious Diseases"},{"issue":"10223","key":"10.1002\/14651858.CD013600-BIB0105|cit105","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD013600-BIB0106|cit106","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1378\/chest.12-2907","article-title":"Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection","volume":"144","author":"Hung","year":"2013","journal-title":"Chest"},{"issue":"12","key":"10.1002\/14651858.CD013600-BIB0107|cit107","doi-asserted-by":"publisher","first-page":"e137","DOI":"10.3346\/jkms.2020.35.e137","article-title":"Understanding and interpretation of case fatality rate of coronavirus disease 2019","volume":"35","author":"","year":"2020","journal-title":"Journal of Korean Medical Science"},{"issue":"1-2","key":"10.1002\/14651858.CD013600-BIB0108|cit108","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.virusres.2011.09.022","article-title":"Immune responses to influenza virus infection","volume":"162","author":"Kreijtz","year":"2011","journal-title":"Virus Research"},{"key":"10.1002\/14651858.CD013600-BIB0109|cit109","doi-asserted-by":"crossref","unstructured":"Lauer SA Grantz KH Bi Q Jones FK Zheng Q Meredith HR The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application Annals of Internal Medicine 2020 10.7326\/M20-0504","DOI":"10.7326\/M20-0504"},{"key":"10.1002\/14651858.CD013600-BIB0110|cit110","doi-asserted-by":"crossref","unstructured":"Lefebvre C Glanville J Briscoe S Littlewood A Marshall C Metzendorf MI Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019 Available from www.training.cochrane.org\/handbook","DOI":"10.1002\/9781119536604.ch4"},{"key":"10.1002\/14651858.CD013600-BIB0111|cit111","doi-asserted-by":"crossref","unstructured":"Li T Higgins JP Deeks JJ editor(s) Chapter 5: Collecting data. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019 Available from www.training.cochrane.org\/handbook","DOI":"10.1002\/9781119536604"},{"issue":"3","key":"10.1002\/14651858.CD013600-BIB0112|cit112","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S1470-2045(20)30096-6","article-title":"Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China","volume":"21","author":"Liang","year":"2020","journal-title":"Lancet Oncology"},{"issue":"8","key":"10.1002\/14651858.CD013600-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"599","DOI":"10.7326\/0003-4819-145-8-200610170-00139","article-title":"Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?","volume":"145","author":"Luke","year":"2006","journal-title":"Annals of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD013600-BIB0114|cit114","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1093\/infdis\/jiu396","article-title":"The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis","volume":"211","author":"Mair-Jenkins","year":"2015","journal-title":"Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD013600-BIB0115|cit115","unstructured":"Microsoft Corporation, available at: office.microsoft.com\/excel Mircosoft Excel Microsoft Corporation 2018"},{"issue":"1","key":"10.1002\/14651858.CD013600-BIB0116|cit116","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/j.1440-1843.2006.00783.x","article-title":"Longitudinal profile of antibodies against SARS-coronavirus in SARS patients and their clinical significance","volume":"11","author":"Mo","year":"2006","journal-title":"Respirology"},{"issue":"10","key":"10.1002\/14651858.CD013600-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"Journal of Clinical Epidemiology"},{"issue":"3","key":"10.1002\/14651858.CD013600-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1093\/clinids\/19.3.500","article-title":"Antibody-dependent enhancement of infection and the pathogenesis of viral disease","volume":"19","author":"Morens","year":"1994","journal-title":"Clinical Infectious Diseases"},{"issue":"4","key":"10.1002\/14651858.CD013600-BIB0119|cit119","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008205.pub3","article-title":"Hepatic late adverse effects after antineoplastic treatment for childhood cancer","author":"Mulder","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD013600-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/vox.12573","article-title":"Transfusion-related acute lung injury risk mitigation: an update","volume":"112","author":"Otrock","year":"2017","journal-title":"Vox Sanguinis"},{"key":"10.1002\/14651858.CD013600-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"65S","DOI":"10.1111\/j.1537-2995.2012.03663.x","article-title":"Adverse effects of plasma transfusion","volume":"52 Suppl 1","author":"Pandey","year":"2012","journal-title":"Transfusion"},{"issue":"24","key":"10.1002\/14651858.CD013600-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"issue":"10","key":"10.1002\/14651858.CD013600-BIB0123|cit123","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.3201\/eid2210.160706","article-title":"Persistence of antibodies against Middle East respiratory syndrome coronavirus","volume":"22","author":"Payne","year":"2016","journal-title":"Emerging Infectious Disease Journal"},{"key":"10.1002\/14651858.CD013600-BIB0124|cit124","doi-asserted-by":"crossref","unstructured":"Reeves BC Deeks JJ Higgins JP Shea B Tugwell P Wells GA Chapter 24: Including non-randomized studies on intervention effects. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions V ersion 6.0 (updated July 2019). Cochrane, 2019 Available from www.training.cochrane.org\/handbook","DOI":"10.1002\/9781119536604.ch24"},{"key":"10.1002\/14651858.CD013600-BIB0125|cit125","unstructured":"The Cochrane Collaboration Review Manager Web (RevMan Web) 2019"},{"key":"10.1002\/14651858.CD013600-BIB0126|cit126","doi-asserted-by":"crossref","unstructured":"Ricke D Malone R Medical countermeasures analysis of 2019-nCoV and vaccine risks for antibody-dependent enhancement (ADE) www.preprints.org\/manuscript\/202003.0138\/v1 2020 2020030138 10.20944\/preprints202003.0138.v1","DOI":"10.20944\/preprints202003.0138.v1"},{"issue":"6","key":"10.1002\/14651858.CD013600-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1093\/infdis\/171.6.1387","article-title":"Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum","volume":"171","author":"Robbins","year":"1995","journal-title":"Journal of Infectious Diseases"},{"issue":"2","key":"10.1002\/14651858.CD013600-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1423-0410.2010.01374.x","article-title":"A comparison of methods of pathogen inactivation of FFP","volume":"100","author":"Rock","year":"2011","journal-title":"Vox Sanguinis"},{"key":"10.1002\/14651858.CD013600-BIB0129|cit129","doi-asserted-by":"crossref","unstructured":"Sch\u00fcnemann HJ Vist GE Higgins JP Santesso N Deeks JJ Glasziou P Chapter 15: Interpreting results and drawing conclusions. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s) Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019 Available from www.training.cochrane.org\/handbook","DOI":"10.1002\/9781119536604.ch15"},{"issue":"4","key":"10.1002\/14651858.CD013600-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"259","DOI":"10.7326\/0003-4819-121-4-199408150-00004","article-title":"Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors","volume":"121","author":"Sekul","year":"1994","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD013600-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD013600-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"3","key":"10.1002\/14651858.CD013600-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.tmrv.2013.05.004","article-title":"Adverse effects of human immunoglobulin therapy","volume":"27","author":"Stiehm","year":"2013","journal-title":"Transfusion Medicine Reviews"},{"key":"10.1002\/14651858.CD013600-BIB0134|cit134","doi-asserted-by":"crossref","unstructured":"Team NCPERE Vital surveillances: the epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) - China China CDC Weekly 2020 2 8 113 22 10.3760\/cma.j.issn.0254-6450.2020.02.003","DOI":"10.46234\/ccdcw2020.032"},{"key":"10.1002\/14651858.CD013600-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"issue":"2","key":"10.1002\/14651858.CD013600-BIB0136|cit136","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.34172\/jrip.2020.19","article-title":"COVID-19 interactions with angiotensin-converting enzyme 2 (ACE2) and the kinin system; looking at a potential treatment","volume":"9","author":"Tolouian","year":"2020","journal-title":"Journal of Renal Injury Prevention"},{"key":"10.1002\/14651858.CD013600-BIB0137|cit137","doi-asserted-by":"publisher","DOI":"10.20944\/preprints202004.0023.v1","article-title":"Kinins and cytokines in COVID-19: a comprehensive pathophysiological approach","volume":"2020040023","author":"Van de Veerdonk","journal-title":"Preprints 2020"},{"issue":"5","key":"10.1002\/14651858.CD013600-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"e02015","DOI":"10.1128\/JVI.02015-19","article-title":"Molecular mechanism for antibody-dependent enhancement of coronavirus entry","volume":"94","author":"Wan","year":"2020","journal-title":"Journal of Virology"},{"issue":"2","key":"10.1002\/14651858.CD013600-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.bbrc.2014.07.090","article-title":"Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins","volume":"451","author":"","year":"2014","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1002\/14651858.CD013600-BIB0140|cit140","unstructured":"World Health Organization (WHO) Cumulative number of reported probable cases of SARS www.who.int\/csr\/sars\/country\/2003_07_11\/en\/"},{"key":"10.1002\/14651858.CD013600-BIB0141|cit141","unstructured":"World Health Organization (WHO) Middle East respiratory syndrome coronavirus (MERS-CoV) www.who.int\/emergencies\/mers-cov\/en\/"},{"key":"#cr-split#-10.1002\/14651858.CD013600-BIB0142|cit142.1","unstructured":"World Health Organization (WHO) Report of the WHO-China Joint Mission on coronavirus disease 2019 (COVID-19)"},{"key":"#cr-split#-10.1002\/14651858.CD013600-BIB0142|cit142.2","unstructured":"February 2020 Available at www.who.int\/docs\/default-source\/coronaviruse\/who-china-joint-mission-on-covid-19-final-report"},{"key":"10.1002\/14651858.CD013600-BIB0143|cit143","unstructured":"World Health Organization (WHO) Rolling updates on coronavirus diseases (COVID-19) www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/events-as-they-happen"},{"key":"10.1002\/14651858.CD013600-BIB0144|cit144","unstructured":"World Health Organization (WHO) Coronavirus disease (COVID-2019) situation report-105; 4 May 2020 Available at www.who.int\/docs\/default-source\/coronaviruse\/situation-reports\/20200504-covid-19-sitrep-105.pdf"},{"key":"10.1002\/14651858.CD013600-BIB0145|cit145","doi-asserted-by":"crossref","unstructured":"World Health Organization (WHO) Clinical management of severe acute respiratory infection (SARI) when COVID19 disease is suspected: interim guidance World Health Organization 2020 WHO\/2019-nCoV\/clinical\/2020.4","DOI":"10.15557\/PiMR.2020.0003"},{"key":"10.1002\/14651858.CD013600-BIB0146|cit146","doi-asserted-by":"crossref","unstructured":"Wu C Chen X Cai Y Xia J Zhou X Xu S Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China JAMA Internal Medicine 2020 10.1001\/jamainternmed.2020.0994","DOI":"10.1001\/jamainternmed.2020.0994"},{"key":"10.1002\/14651858.CD013600-BIB0147|cit147","doi-asserted-by":"crossref","unstructured":"Wu F Wang A Liu M Wang Q Chen J Xia S Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications medRxiv 110.1101\/2020.03.30.2004736","DOI":"10.2139\/ssrn.3566211"},{"issue":"4","key":"10.1002\/14651858.CD013600-BIB0148|cit148","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/S2213-2600(20)30076-X","article-title":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome","volume":"8","author":"Xu","year":"2020","journal-title":"Lancet Respiratory Medicine"},{"key":"10.1002\/14651858.CD013600-BIB0149|cit149","doi-asserted-by":"crossref","unstructured":"Zhao J Yuan Q Wang H Liu W Liao X Su Y Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019 medRxiv 2020 10.1101\/2020.03.02.20030189","DOI":"10.2139\/ssrn.3546052"},{"key":"10.1002\/14651858.CD013600-BIB0150|cit150","unstructured":"Piechotta V Valk SJ \u00a0Chai KL Wood EM \u00a0Lamikanra A \u00a0Kimber C Safety and effectiveness of convalescent plasma or hyperimmune globulin for people with COVID-19: a rapid review available at:\u00a0doi.org\/10.17605\/OSF.IO\/DWF53"}],"updated-by":[{"DOI":"10.1002\/14651858.cd013600.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T00:00:00Z","timestamp":1594339200000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,10,23]],"date-time":"2022-10-23T19:02:36Z","timestamp":1666551756000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD013600"}},"subtitle":[],"editor":[{"name":"Cochrane Haematology Group","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2020,5,14]]},"references-count":151,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd013600","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD013600.pub2","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,14]]}}}